UNSPSC 51181604: Thyroid-stimulating hormone or thyrotropin or thyrotropin alfa

This classification denotes a pituitary agent with the molecular formula C975H1513N267O304S26, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AVX3D5A4LM, more generally known as thyrotropin alfa. European Medicines Agency schedules thyrotropin alfa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12610MIG. The term THYROTROPIN ALFA is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 12 no. 2 1999, list 40.

UNSPSC 51181604 Thyroid-stimulating hormone or thyrotropin or thyrotropin alfa is a Commodity code covering pharmaceutical products distributed through state and local government health and human services facilities. Recent solicitation activity shows state and local buyers procuring generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing vehicles, with demand driven by state health departments, Medicaid programs, public hospitals, and corrections systems. Vendors supply products meeting current Good Manufacturing Practices certification and Drug Supply Chain Security Act compliance, working through authorized pharmaceutical wholesalers and submitting detailed product data including National Drug Codes, SKUs, UPCs, strength, dosage form, and packaging configurations. Pricing is typically structured as fixed price, net price formats, or WAC-minus discount arrangements, with vendors absorbing administrative fees of 2–3 percent on all contract purchases and facing performance penalties for late reporting or missed onboarding timelines.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving participating state and local facilities across Minnesota and Oregon. Evaluation criteria weight price competitiveness at 75 percent, with smaller weightings on fixed pricing (10 percent), compliance with administrative data formats (5 percent), EDI capability (5 percent), and agreement to the 3 percent administrative fee (5 percent). Awarded vendors will be provided to authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—by May 15, 2026, with resulting agreements effective July 1, 2026. The contract term is two years for new vendors, with incumbent vendor amendments aligning through June 30, 2028. Submissions require comprehensive insurance coverage including $5 million commercial general liability, $2 million network security and privacy liability, and $2 million professional liability, with all products compliant with FDA requirements and minimum one-year expiration dates from manufacture.